Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2015Drug Design Development and TherapyOpen Access

The role of dasatinib in the management ofchronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBaoan ChenZhongda Hospital Southeast UniversityRCRunzhe ChenSun Yat-sen University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chen et al. (2015) studied this question.

synapsesocial.com/papers/6a1d19f7cc9f7df1b704e147https://doi.org/10.2147/dddt.s80207
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias2006 · 1,789 citations
  2. 2Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up2009 · 172 citations
  3. 3BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid leukemia2013 · 8 citations
  4. 4Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia2010 · 64 citations
  5. 5Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial2007 · 378 citations